Adagene Clears China NMPA IND For ADG138 In Solid Tumors, Phase 1 Set For Q4 2026

Adagene Inc. (ADAG) received clearance from China's National Medicinal Products Administration for an investigational new drug application for ADG138 in solid tumors, the clinical-stage biotechnology company said on Tuesday, September 22, 2026. The company plans to begin a Phase 1 trial in the fourth quarter of 2026. ADG138 is the company's investigational therapy for solid tumors. Financial terms and trial specifics were not disclosed.